ASCO 2023 | Novel advances in PD-1 refractory melanoma

Adnan Khattak, MBBS, FRACP, Royal Perth Hospital, Perth, Australia, explores the emerging treatment strategies for PD-1 refractory melanoma, including neoadjuvant therapy. Preoperative immune checkpoint inhibitors have been a promising treatment avenue, where their efficacy can be assessed early. Patients who have a robust complete response tend to have better outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.